Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $36.7 million.

  • Aytu Biopharma's Accumulated Expenses rose 8.83% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.7 million, marking a year-over-year increase of 8.83%. This contributed to the annual value of $38.2 million for FY2025, which is 0.06% up from last year.
  • As of Q3 2025, Aytu Biopharma's Accumulated Expenses stood at $36.7 million, which was down 3.84% from $38.2 million recorded in Q2 2025.
  • Aytu Biopharma's 5-year Accumulated Expenses high stood at $57.2 million for Q2 2021, and its period low was $33.7 million during Q3 2024.
  • In the last 3 years, Aytu Biopharma's Accumulated Expenses had a median value of $40.7 million in 2023 and averaged $41.1 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 548.10% in 2021, then fell by 23.81% in 2022.
  • MRQ analysis of 5 years shows Aytu Biopharma's Accumulated Expenses stood at $50.7 million in 2021, then decreased by 18.68% to $41.2 million in 2022, then rose by 5.33% to $43.4 million in 2023, then dropped by 9.31% to $39.4 million in 2024, then dropped by 6.79% to $36.7 million in 2025.
  • Its last three reported values are $36.7 million in Q3 2025, $38.2 million for Q2 2025, and $41.7 million during Q1 2025.